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Abstract
Introduction Systemic lupus erythematosus (SLE) is an
archetypal autoimmune disease, involving multiple organ
systems with varying course and prognosis. However, there is a
paucity of clinical data regarding prognostic factors in SLE
patients admitted to the intensive care unit (ICU).
Methods From January 1992 to December 2000, all patients
admitted to the ICU with a diagnosis of SLE were included.
Patients were excluded if the diagnosis of SLE was established
at or after ICU admission. A multivariate logistic regression
model was applied using Acute Physiology and Chronic Health
Evaluation II scores and variables that were at least moderately
associated (P < 0.2) with survival in the univariate analysis.
Results A total of 51 patients meeting the criteria were
included. The mortality rate was 47%. The most common cause
of admission was pneumonia with acute respiratory distress
syndrome. Multivariate logistic regression analysis showed that
intracranial haemorrhage occurring while the patient was in the
ICU (relative risk = 18.68), complicating gastrointestinal
bleeding (relative risk = 6.97) and concurrent septic shock
(relative risk = 77.06) were associated with greater risk of dying,
whereas causes of ICU admission and Acute Physiology and
Chronic Health Evaluation II score were not significantly
associated with death.
Conclusion The mortality rate in critically ill SLE patients was
high. Gastrointestinal bleeding, intracranial haemorrhage and
septic shock were significant prognostic factors in SLE patients
admitted to the ICU.
Introduction
Systemic lupus erythematosus (SLE) is an archetypal autoim-
mune disease, involving multiple organ systems and with vary-
ing course and prognosis. Even though the survival rate
among SLE patients has improved over the past few decades
[1-3], there remain a host of factors that are associated with
death in SLE patients, including the level of disease activity
and demonstrable organ damage at presentation [4,5]. More-
over, coronary artery disease has increasingly been recog-
nized to be an important cause of death in SLE patients [6]. In
contrast, infections, which develop in the setting of active SLE
under aggressive treatment, are often difficult to identify as a
single cause of death [7]. Effective treatment for SLE has led
to improved prognosis and extended survival times [8,9]. How-
ever, intensive treatment concomitantly results in an increased
number of disease- or therapy-associated complications,
which also require intensive care. Patients with SLE admitted
to the intensive care unit (ICU) mostly present with florid dis-
ease manifestations, with a compendium of pathologies pre-
cipitating the admissions [10]. However, there is a paucity of
clinical data regarding prognostic factors in SLE patients
admitted for intensive care.
APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; ICU = intensive care unit; SLE = systemic 
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In the present study we analyzed prognostic factors in a cohort
of SLE patients admitted to our ICU over the past 8 years, par-
ticularly with respect to causes of ICU admission, severity of
illness and clinical course during the patients' ICU stays.
Materials and methods
Patients
All patients with SLE admitted to the medical ICU of the
National Taiwan University Hospital from January 1992 to
December 2000 were included. Diagnosis of SLE was con-
firmed if the patient fulfilled at least four of the 1982 American
Rheumatism Association revised classification criteria [11].
The exclusion criterion was diagnosis of SLE at or after admis-
sion to the ICU. If the patient was admitted to the ICU more
than once, only data from the first ICU admission were
analyzed.
Data collection
We analyzed the following clinical and laboratory parameters:
age, sex, underlying diseases and associated manifestations
of SLE, causes of admission, Acute Physiology and Chronic
Health Evaluation (APACHE) II score [12], arterial oxygen ten-
sion/inspired fractional oxygen ratio, complete blood count,
characteristics of lesions on chest radiographs, sites of infec-
tion and organisms cultured, treatments administered during
the patient's ICU stay, occurrence of complications, duration
of ICU study and outcome.
The cause of ICU admission was defined as the major problem
necessitating admission to the ICU. This was determined on
the basis of clinical data. Cardiogenic pulmonary oedema is
due to poor cardiac performance. Noncardiogenic pulmonary
oedema is due to fluid overloading of a noncardiogenic cause.
APACHE II scores were calculated using clinical data availa-
ble from the first 24 hours of intensive care. The median
APACHE II score was used as a cutpoint to classify the
patients into high or low score groups. Renal involvement was
defined as urinary excretion of more than 500 mg protein/24
hours, cellular casts not attributable to infection, or abnormal
histology on renal biopsy. Abnormal complete blood count
was defined as haemolytic anaemia or leucopenia (<4 × 109/
l), lymphopenia (<1.5 × 109/l), or thrombocytopenia (<100 ×
109/l) in the absence of offending drugs. Neutropenia was
defined as an absolute neutrophil count under 1.0 × 109/l.
Pneumonia was defined as new and persistent radiographic
opacity, positive sputum culture and any three of the following:
body temperature above 38°C, white blood cell count above
15 × 109/l, increased airway secretions, or worsening gas
exchange [13]. Respiratory failure was defined as arterial oxy-
gen tension below 60 mmHg and/or arterial carbon dioxide
tension of 50 mmHg or greater while the patient was breathing
room air. Acute respiratory distress syndrome (ARDS) was
defined in accordance with to the American–European Con-
sensus Conference on ARDS [14]. Sepsis and septic shock
were defined in accordance with the criteria of Bone and cow-
orkers [15].
Gastrointestinal bleeding was defined as the presence of at
least one of the following: melena, haematemesis, or blood
from nasogastric aspirate over 24 hours. Finally, patient out-
come was classed as death while the patient was in the ICU
or survival to discharge from the ICU.
Statistical analysis
Values are expressed as median (range) for continuous varia-
bles, or as a percentage of the group from which they were
derived for categorical variables. Differences in survival among
subgroups of variables were analyzed by χ2 test or by Fisher's
exact test when necessary. A forward stepwise multivariate
logistic regression model was applied (SPSS 10.0 for Win-
dows; SPSS Inc., Chicago, IL, USA), using APACHE II score
and variables that were at least moderately associated (P <
0.2) with survival in the univariate analysis. P ≤ 0.05 was con-
sidered statistically significant.
Results
Clinical characteristics
From January 1992 to December 2000, a total of 4235
patients were admitted to the ICU. Of these, 51 SLE patients
were included in the present study. The clinical features of the
51 SLE patients are summarized in Table 1. Three of the 51
patients had associated autoimmune disease in addition to
SLE, including one with polymyositis, one with Graves' dis-
ease and one with psoriasis. The most common disease man-
ifestation among the 51 SLE patients before ICU admission
was mucocutaneous involvement (44 [86.2%]), followed by
renal involvement (37 [72.5%]). The median duration from
diagnosis of SLE to ICU admission was 27 months (range 1–
288 months). Forty-seven patients (92.2%) were receiving
corticosteroid medication before ICU admission, with a mean
equivalent dose of 20 mg/day prednisolone.
Causes of admission
A total of 60 ICU admissions were included in the present
study, with the annual number of admissions of SLE patients
fluctuating. No trend favouring any particular cause of ICU
admission was identified during the course of the study. There
were seven patients with more than one admission to the ICU,
including five patients with two admissions and two with three
admissions. The causes of ICU admission are summarized in
Table 2. The most common cause of admission to the ICU was
pneumonia with ARDS (14 [23%]).
Noninfectious causes
Thirty-three (55.0%) admissions to the ICU were due to non-
infectious problems. For patients in the cardiogenic category,
heart failure was the major cause of admission, including car-
diogenic shock and cardiogenic pulmonary oedema. Nine
(15.0%) admissions were for pericardial effusion. AmongAvailable online http://ccforum.com/content/9/3/R177
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them, three patients were admitted because of cardiac tam-
ponade. Eleven patients had noninfectious pulmonary prob-
lems, and noncardiogenic pulmonary oedema was the most
common cause. Among the patients with noncardiogenic pul-
monary oedema, all were due to acute deterioration in renal
function. For patients in the neurological category, status epi-
lepticus was the most common cause of admission, and most
(71.4%) had a previous history of seizures.
Infectious causes
Twenty-seven admissions (45.0%) to the ICU were due to
infectious diseases, including pneumonia with ARDS and sep-
sis of extrapulmonary origin (Table 3). The infectious patho-
gens identified in SLE patients varied considerably. Eleven
had positive blood culture results, including six Gram-negative
bacilli, four Gram-positive cocci and one fungaemia. Pseu-
domonas aeruginosa (n = 3), Salmonella (n = 2; groups B and
C) and Escherichia coli (n = 1) accounted for the cases of
Gram-negative sepsis, whereas Staphylococcus aureus (n =
2; including one methicillin-resistant S aureus), Staphylococ-
cus epidermidis (n = 1) and Streptococcus pneumoniae (n =
1) were the major pathogens of Gram-positive sepsis. Three
patients had confirmed positive pleural effusion culture,
including one methicillin-resistant S aureus, one S pneumo-
niae and one Acinetobacter baumannii. One patient suffered
from disseminated tuberculosis with tuberculous bacilli iso-
lated from pleural effusion and ascites. One patient had tuber-
culous meningitis, with tuberculous bacilli isolated from the
cerebrospinal fluid.
Clinical course, treatment and outcome
The clinical courses and outcomes in the 51 patients for their
first admissions are summarized in Table 3. In order to assess
the possible effect of repeat measurement, the results were
analyzed separately by all admissions and first admission only;
no significant differences were noted.
Forty-one patients were receiving steroid therapy to control
the activity of the disease, including seven receiving pulse
therapy (equivalent dose of >625 mg/day prednisolone). Also,
35 patients required mechanical ventilation, with three under-
going tracheotomy because of prolonged intubation. Nineteen
patients needed dialysis, including 11 who received continu-
ous venovenous haemofiltration because of unstable
haemodynamics.
Fifteen (29.4%) had gastrointestinal bleeding during their ICU
stay, which manifested as melena, haematemesis, or blood in
the nasogastric aspirate. The rate of steroid use was higher in
patients with gastrointestinal bleeding than in those who had
no gastrointestinal bleeding (87.5% versus 75%), but the
association was not statistically significant (P = 0.253). No
evidence of mesenteric vasculitis could be demonstrated in
the patients with gastrointestinal bleeding. One of them had
colon perforation and underwent surgical intervention,
whereas in the others the bleeding was controlled by medica-
tion without the need for fluid resuscitation or blood compo-
nent therapy. Four developed pneumothorax during their ICU
stay and were treated by tube thoracotomy for drainage.
Intracranial haemorrhage occurred in six patients (11.7%),
including four with brainstem haemorrhage, one with sub-
arachnoid haemorrhage and one with frontal lobe haemor-
rhage. Three patients were admitted to the ICU because of
intracranial haemorrhage; these were not included in the six
patients.
Whereas the overall mortality of the non-SLE ICU population
was 29.0% from 1992 to 2000, the mortality rate for SLE
patients admitted to the ICU was 47.0%.
Prognostic factors
To identify prognostic factors for death in SLE patients admit-
ted to the ICU, univariate and multivariate analyses for these
factors were conducted. We performed the analyses using
data from the first admission of the patients. Table 4 summa-
rizes the variables with at least moderate influence (P < 0.2)
on mortality, as determined by univariate analysis. Patients
with abnormal complete blood count on admission (P =
0.005), with intracranial haemorrhage occurring while in the
ICU (P = 0.018), with complicating gastrointestinal bleeding
in the ICU (P = 0.01), and with concurrent septic shock in the
ICU (P < 0.001) were at higher risk of mortality. Patients who
had sepsis without pulmonary infection as a cause of admis-
sion were at lower risk of mortality (P = 0.04).
Multivariate logistic regression analysis showed that the pres-
ence of gastrointestinal bleeding, intracranial haemorrhage
and septic shock significantly increased the likelihood of
Table 1
Clinical features of patients with systemic lupus erythematosus 
admitted to the intensive care unit
Clinical feature Value
Age (years; mean [range]) 29 (12–55)
Female (n [%]) 47 (92.2)
APACHE II score (mean [range]) 19 (9–37)
White blood cell count (×109/l; mean [range]) 8.0 (2.2–136.0)
Platelet count (×109/l; mean [range]) 132.0 (17.0–474.0)
Thrombocytopenia (n [%]) 23 (45.1)
Neutropenia (n [%]) 2 (3.9)
Pulmonary manifestations (n [%])
Consolidation 29 (56.9)
Interstitial 19 (37.3)
Pleural effusion 25 (49.0)
APACHE, Acute Physiology and Chronic Health Evaluation.Critical Care    Vol 9 No 3    Hsu et al.
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dying, whereas causes of ICU admission and APACHE II
scores had no influence (Table 5).
Discussion
We found that the mortality rate was high in SLE patients
admitted to the ICU. The most common cause of ICU admis-
sion was lung injury/respiratory failure, followed by sepsis/sys-
temic inflammatory response syndrome, cardiogenic causes
and neurological disorders. The occurrences of gastrointesti-
nal bleeding, intracranial haemorrhage and septic shock dur-
ing the ICU stay significantly increased the likelihood of dying.
Recent studies [1-3] have demonstrated a greater reduction in
mortality in SLE patients than in the general population over
the past few decades. The 10-year survival rate in retrospec-
tive series has been 75–85%, with more than 90% of patients
surviving longer than 5 years [1-3,16,17]. Nevertheless, out-
comes and prognosis in acutely ill SLE patients admitted to
the ICU have rarely been investigated. In 1996, Ansell and
coworkers [10] reported a retrospective study of SLE patients
in the ICUs of two hospitals. They investigated a total of 30
patients and demonstrated high mortality rate in SLE patients
in critical care units (47%), similar to the rate in the present
study (47%). However, they found that the only pretreatment
factor that predicted a poor outcome was the presence of
renal involvement due to SLE per se. Survival analysis for
patients with and those without renal involvement revealed a
difference in long-term survival (maximum follow-up period of
120 months) but not in ICU mortality rate. A multivariate anal-
ysis of prognostic factors was not performed in that study
because of the small number of patients included. We
performed a multivariate analysis in 51 SLE patients admitted
to the ICU. Although renal involvement due to SLE was not
predictive of patient outcome in the ICU, we identified more
than one variable influencing mortality rate in our study.
The average ICU mortality from 1992 to 2000 in our hospital
was around 29%, which is lower than the mortality rate in SLE
patients admitted to the ICU (47%). The other ICU patients
might have different clinical characteristics compared with
Table 2
Causes of admission to the intensive care unit in critically ill patients with systemic lupus erythematosus
Cause of admission Total Noninfectious Infectious
Cardiogenic 11 (18.3)
Cardiogenic shock 4 (6.6)
Ventricular arrhythmia 2 (3.3)
Cardiogenic pulmonary oedema 2 (3.3)
Pericardial effusion with cardiac tamponade 3 (5.0)
Lung injury/respiratory failure 25 (41.6)
Pneumonia with ARDS (including one pulmonary tuberculosis) 14 (23.3)
Noncardiogenic pulmonary oedema 7 (11.6)
Interstitial pneumonitis 1 (1.6)
Pulmonary embolism 1 (1.6)
Haemothorax 1 (1.6)
Upper airway obstruction 1 (1.6)
Sepsis without pulmonary infection 13 (21.7)
Unknown origin of infection 9 (15.0)
Infective endocarditis 1 (1.6)
Peritonitis 1 (1.6)
Cellulitis 1 (1.6)
Meningoencephalitis (tuberculous) 1 (1.6)
Neurological disorder 11 (18.3)
Status epilepticus 7 (11.6)
Intracranial haemorrhage on admission 3 (5.0)
Ischaemic stroke 1 (1.6)
Values are expressed as number (%). ARDS, acute respiratory distress syndrome.Available online http://ccforum.com/content/9/3/R177
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SLE patients. The data show that the SLE patients requiring
ICU admission had poorer outcomes than did other critically ill
patients admitted to the ICU.
In one study [4], renal damage, thrombocytopenia, lung
involvement, SLE Disease Activity Index greater than or equal
to 20 at presentation, and age 50 years or older at diagnosis
were all predictive of mortality in univariate and multivariate
analyses in SLE patients over a 20-year follow-up period.
However, the rate of ICU admission in these patients was not
mentioned. In the present study these factors were not asso-
ciated with ICU and in-hospital mortality in SLE patients. The
APACHE II score was of little value in predicting outcome,
probably because it could not effectively estimate the influ-
ence of underlying systemic diseases and the occurrence of
possible complications in the SLE patients admitted to the
ICU. Gastrointestinal bleeding, intracranial haemorrhage and
septic shock during the ICU stay were associated with a
greater risk of death, indicating that clinical course and medi-
cal care – not the pretreatment morbidity and acute physiolog-
ical condition – play key roles in influencing the prognosis of
SLE patients in the ICU.
The incidence of gastrointestinal haemorrhage in SLE patients
is approximately 5% [18]. Previous studies showed that the
incidence of gastrointestinal haemorrhage among the general
population of patients admitted to the ICU was 3.5–5%
[19,20]. In the present study we found that the incidence of
gastrointestinal bleeding among SLE patients was much
higher (Table 1) than that in the general cohort of patients
admitted to the ICU.
We also found intracranial haemorrhage, including brainstem
haemorrhage, subarachnoid haemorrhage and frontal lobe
haemorrhage, to be a factor that increases the risk of dying.
Acute stroke (infarction or intracranial bleeding) in patients
admitted to the ICU with non-neurological problems occurred
in 1.25% [21]. Subarachnoid haemorrhage occurred in 10 out
of 258 patients with SLE in a previous study [22]. Neverthe-
less, the actual frequency of and factors contributing to intrac-
ranial haemorrhage in SLE patients remain undefined. In the
ICU it is often difficult to make a diagnosis of cerebrovascular
accident in SLE patients with altered mental status, metabo-
lism-induced focal motor abnormalities, or impaired speech
because of mechanical ventilation. On the other hand, many
factors may contribute to the pathogenesis of acute stroke,
including coagulopathy, hypertension, long-term steroid use
Table 3
Disease courses and outcomes of patients with systemic lupus 
erythematosus admitted to the intensive care unit
Courses and outcomes Number (%)
Need for mechanical ventilation 35 (68.6)
Steroid use in the ICU 41 (80.4)
Total parenteral nutrition 8 (15.6)
Continuous venovenous haemofiltration 11 (21.6)
Peritoneal dialysis 4 (7.8)
Haemodialysis 16 (31.3)
Operation 6 (11.8)
Gastrointestinal bleeding in the ICU 15 (29.4)
Intracranial haemorrhage in the ICU 6 (11.8)
Pneumothorax in the ICU 4 (7.8)
Septic shock in the ICU 15 (29.4)
Length of ICU stay (days; mean [range]) 7 (1–68)
Death in the ICU 24 (47.0)
Death in the hospital 24 (47.0)
ICU, intensive care unit.
Table 4
Variables that possibly influence the mortality of patients with 
systemic lupus erythematosus admitted to the intensive care 
unit: univariate analysis
Variable n Died (n [%]) P
APACHE II score
>19 (median value) 24 11 (45.8) 0.361
≤ 19 27 9 (33.3)
Previous seizure attack before admission
Yes 14 3 (21.4) 0.110
No 37 17 (45.9)
Sepsis without pulmonary infection on admission
Yes 13 2 (15.4) 0.04
No 38 18 (47.4)
Abnormal complete blood count
Yes 41 23 (50.0) 0.005
No 10 0 (0)
Gastrointestinal bleeding in the ICU
Yes 15 11 (68.7) 0.01
No 36 13 (29.5)
Intracranial haemorrhage in the ICU
Yes 6 5 (83.3) 0.018
No 45 15 (33.3)
Concurrent septic shock in the ICU
Yes 15 14 (93.3) <0.001
No 36 6 (16.7)
Included are Acute Physiology and Chronic Health Evaluation 
(APACHE) II score and variables moderately associated (P < 0.2) 
with survival. ICU, intensive care unitCritical Care    Vol 9 No 3    Hsu et al.
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and lipid disorders. Early diagnosis and appropriate treatment
of intracranial haemorrhage are therefore important aspects of
intensive care for SLE patients.
We identified various infectious pathogens in SLE patients.
The immunocompromised status associated with the disease
itself appears to be primarily responsible for the development
of infectious complications [23]. Glucocorticoids and immu-
nosuppressive drugs may increase the risk for infections and
the number of types of infections that develop. We found the
pathogens in SLE patients in the ICU to vary considerably, and
the development of septic shock is a major prognostic factor
in these patients. In many patients infections develop in the
setting of active lupus undergoing aggressive treatment; alter-
natively, the manifestations of active lupus can mimic infection
clinically. It is sometimes difficult to clarify the site of infection
and to initiate antimicrobial therapy promptly. Godeau and
coworkers [24] found corticosteroid administration to be
related to in-hospital mortality in patients with systemic rheu-
matic disease who were admitted to the ICU. However, that
phenomenon did not present in our study. The differences
between studies might be due to several factors. First, our
study included a relatively small number of patients. Second, a
high percentage of patients received steroid treatment before
ICU admission and during the ICU stay (92.2% and 80.4%,
respectively); more SLE patients not receiving steroid treat-
ment would be necessary to demonstrate a difference
between these two groups. However, Godeau and coworkers
[24] found corticosteroid treatment to be related to in-hospital
mortality, but other immunosuppressive treatments were not
related to outcomes in their study. Further large prospective
studies might provide more clinical information about the rela-
tionship between immunosuppressive agents and outcomes
in this patient population.
There some limitations to the present study. Because of the
relatively small number of patients included, the patients stud-
ied may not be representative the clinical features of the SLE
population. Also, because of the retrospective design, the
study lacks information on initial disease activity and laboratory
data at the first visit to the hospital, although these clinical fea-
tures may change after medical treatment but before ICU
admission. Initial parameters may have little influence on ICU
outcomes, but this could not be tested in the present study.
Conclusion
The mortality rate in critically ill patients with SLE is high. We
posit that gastrointestinal bleeding, intracranial haemorrhage
and septic shock are significant prognostic factors in SLE
patients admitted to the ICU. In contrast, the causes of ICU
admission and APACHE II score are not significantly associ-
ated with mortality.
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